ReviewBMC medical research methodology2025
Randomization in the age of platform trials: unexplored challenges and some potential solutions.
Review in BMC medical research methodology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction: Randomization in the age of platform trials: unexplored challenges and some potential solutions.BMC medical research methodology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
14 authors.
Funding
Abstract
While platform trials have several benefits with their adaptive features, randomization challenges become of central relevance to the design and execution of a platform trial. This paper intends to address these challenges and explore some potential solutions. A platform type of clinical trial is a clinical trial design where multiple interventions are investigated simultaneously often against partly or fully shared controls, with new treatment arms added and completed treatment arms removed. Unequal allocation is often used in platform trials to improve statistical efficiency, deliver benefits to trial participants, and control the speed of enrollment in different treatment arms. Changes to the allocation ratio may be required after an interim analysis even when the number of treatment arms remains constant, for example, in a platform trial with response-adaptive randomization. To deliver the design efficiencies promised by the carefully optimized allocation ratio or simply to ensure a pre-determined allocation ratio, randomization methods that keep allocation proportions close to the target allocation ratio throughout randomization are helpful. Other situations commonly occurring in platform trials require special considerations for randomization methods and in some cases new classes of randomization methods. Such specific platform features include the requirement to accommodate differences in eligibility for different treatments, the need to ensure partial blinding with a 2-step randomization when mode of administration for different interventions is conspicuously different and full blinding is unfeasible, the objective to balance through dynamic randomization multiple prognostic factors or the need to accommodate limited drug supplies at the numerous trial centers, among others. The key to a successful execution of a complex randomization in the platform trial is the expert design of the Interactive Response Technology (IRT) system, where the system is built at the master protocol level and existing and potential randomization needs are incorporated from the outset. An additional, often overlooked, challenge when working with unequal allocation ratios and randomization methods to attain these, is the importance of preserving the unconditional allocation ratio at every allocation. Failure to do so might lead to a selection and evaluation bias even in double-blind trials, accidental bias, and reduced power of the re-randomization test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.